These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6387890)

  • 21. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
    Von Hoegen P; Weber E; Schirrmacher V
    Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
    Kim TS; Russell SJ; Collins MK; Cohen EP
    Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex.
    Schrader JW; Edelman GM
    J Exp Med; 1977 Mar; 145(3):523-39. PubMed ID: 233918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of the recognition by cytotoxic T lymphocytes (CTL) of target membrane antigens after fusion with whole cells.
    Baird B; Henkart P
    Cell Immunol; 1983 Feb; 75(2):312-27. PubMed ID: 6600974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
    Wehrmaker A; Lehmann V; Dröge W
    Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-induced redistribution of normal and tumor associated surface antigens.
    Yefenof E; Klein G
    Exp Cell Res; 1974 Oct; 88(2):217-24. PubMed ID: 4372068
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL.
    Kaneko Y; Natsuume-Sakai S; Migita S
    J Immunol; 1978 Aug; 121(2):427-37. PubMed ID: 79604
    [No Abstract]   [Full Text] [Related]  

  • 29. Recognition of Rous sarcoma virus-induced tumor antigens by cytotoxic T lymphocytes (CTL): studies on specificity of killing by CTL employing H-2 congenic and recombinant mouse tumor cells.
    Haraguchi S; Kurakata S; Fujii T; Matsuo T; Yoshida TO
    Cell Immunol; 1987 Apr; 105(2):340-54. PubMed ID: 2436809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxic T lymphocytes induced against allogeneic I-region determinants react with Ia molecules on trinitrophenyl-conjugated syngeneic target cells.
    Billings P; Burakoff S; Dorf ME; Benacerraf B
    J Exp Med; 1977 Aug; 146(2):623-8. PubMed ID: 69009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR
    J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of cytotoxic thyroglobulin-specific T cell hybridomas.
    Remy JJ; Texier B; Chiocchia G; Charreire J
    J Immunol; 1989 Feb; 142(4):1129-33. PubMed ID: 2464639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GD2 oligosaccharide: target for cytotoxic T lymphocytes.
    Zhao XJ; Cheung NK
    J Exp Med; 1995 Jul; 182(1):67-74. PubMed ID: 7540657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour-associated transplantation antigen in sera of rats with large RSV-induced sarcomas.
    el Ridi R; Bubeník H
    Int J Cancer; 1975 Jul; 16(1):83-90. PubMed ID: 170216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic T lymphocytes specific for I region determinants do not require interactions with H-2K or D gene products.
    Billings P; Burakoff S; Dorf ME; Benacerraf B
    J Exp Med; 1977 May; 145(5):1387-92. PubMed ID: 67179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific lysis of antigenically irrelevant cells by cytotoxic T lymphocytes upon insertion of appropriate antigens into the target cell plasma membranes.
    Schick B; Jakobovits A; Sharon N; Berke G
    Transplantation; 1983 Jul; 36(1):84-90. PubMed ID: 6191418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T cells.
    Schrader JW; Edelman GM
    J Exp Med; 1976 Mar; 143(3):601-14. PubMed ID: 1082492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.